1. Discontinuation of enzyme replacement therapy in adults with Pompe disease: Evaluating the European POmpe Consortium stop criteria
- Author
-
H.A. van Kooten, L. Harlaar, N.A.M.E. van der Beek, P.A. van Doorn, A.T. van der Ploeg, E. Brusse, W.L. van der Pol (Chair), I.A.M. Ditters, M.J. Hoogendijk-Boon, H.H. Huidekoper, E.J.O. Kompanje, A. Oskam, W.W.M. Pijnappel, B.J. Sibbles, J.J.A. van den Dorpel, J.M.P. van der Hout, H. van der Kuy, A.G. Vulto, M.A.E.M. Wagenmakers, Neurology, Pediatrics, Public Administration, Intensive Care, Internal Medicine, Clinical Genetics, General Practice, and Pharmacy
- Subjects
Adult ,Male ,0301 basic medicine ,Pediatrics ,medicine.medical_specialty ,Clinical Decision-Making ,Disease ,Expert committee ,03 medical and health sciences ,0302 clinical medicine ,Advanced disease ,Humans ,Medicine ,Enzyme Replacement Therapy ,Prospective Studies ,Genetics (clinical) ,Aged ,Netherlands ,Aged, 80 and over ,Adult patients ,Glycogen Storage Disease Type II ,business.industry ,Authorization ,Enzyme replacement therapy ,Middle Aged ,Discontinuation ,Time of death ,Outcome and Process Assessment, Health Care ,030104 developmental biology ,Neurology ,Practice Guidelines as Topic ,Pediatrics, Perinatology and Child Health ,Female ,Neurology (clinical) ,business ,030217 neurology & neurosurgery - Abstract
Enzyme replacement therapy for Pompe disease received market authorization in 2006. To implement this costly treatment in the Netherlands in the most sensible way, a multidisciplinary expert committee was installed. We evaluated decision making in adult patients in relation to the European POmpe Consortium stop criteria. Of 125 adult Pompe patients, 111 started treatment; subsequently treatment stopped in 24 patients (21%). In 10 patients, treatment was discontinued for medical or personal reasons, as defined in the six stop criteria (median treatment duration: 2.1 years, range: 0.3-14.6 years). Three of these patients continued follow-up (follow-up: 1.3-8.0 years), these patients did not display a more rapid decline after discontinuation. In 14 of 24 patients, therapy ended at time of death. In 10 patients death was related to Pompe disease (median treatment duration: 7.2 years, range: 0.4-10.3 years). All 10 patients were severely affected at start of treatment, treatment had elicited positive effects in eight. The European POmpe Consortium guidelines worked well in decision making on stopping treatment. However, (re)evaluation of the rationale for continuation of treatment in advanced disease stage is not addressed. We suggest to add this to the treatment evaluation and to handle treatment decisions in a multidisciplinary expert team. (C) 2019 The Author(s). Published by Elsevier B.V.
- Published
- 2020
- Full Text
- View/download PDF